Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Biogen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to establish a national system for regulating therapeutic goods, including medicines, medical devices, and blood and blood components, to protect public health and safety. This Act was introduced to address the need for a comprehensive legislative framework that ensures therapeutic goods are safe, of high quality, and effective, and it is administered by the Therapeutic Goods Administration under the Department of Health. The policy objective of this Act is to provide a regulatory environment that supports innovation and access to therapeutic goods while safeguarding the health and safety of the Australian public. The Act includes provisions for the regulation of the importation, supply, and advertising of therapeutic goods, as well as mechanisms for monitoring and enforcing compliance with the standards set forth in the legislation.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide array of therapeutic goods, including medicines, medical devices, and blood and blood components, ensuring they meet specified standards of quality, safety, and efficacy. The Act operates under the Commonwealth and applies to both the manufacture and distribution of therapeutic goods within Australia. It extends to entities such as sponsors, manufacturers, importers, and suppliers, and encompasses various activities including the importation, supply, and advertising of therapeutic goods. The Act’s jurisdictional reach is comprehensive, applying to all states and territories within Australia. Notably, the Act may be subject to modifications and further definitions through subordinate instruments, such as Therapeutic Goods Orders, which provide more detailed regulations and standards. For instance, the Act refers to specific orders like the General Requirements for Labels for Medicines, which detail the labelling standards that must be adhered to. However, the Act does not apply to therapeutic goods that are exempt under the Therapeutic Goods (Exemptions) Order, and certain goods may also be exempt from the operation of the Act under specific conditions.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 provide a mechanism for the Secretary of the Department of Health to give consent for the importation and supply of therapeutic goods that do not fully comply with the standards set by the Therapeutic Goods Administration (TGA). Specifically, Section 14 allows for the importation and supply of goods for special reasons, while Section 14A permits such activities on compassionate grounds. In this case, the Secretary, through a delegate, has granted consent to Biogen Australia Pty Ltd for the importation and supply of dimethyl fumarate (TECFIDERA) capsules 120 mg and 240 mg in blister packs. The consent pertains to batches that do not conform with the labelling requirements of Therapeutic Goods Order No. 69, in that the sponsor name on the label is not the currently registered name, although there have been no changes to the sponsor's address details. This consent is effective from 29 June 2015 and will remain in place until the nominated batches are exhausted. Under the terms of this consent, several obligations are imposed on Biogen Australia Pty Ltd. Firstly, they must adhere to the labels currently approved for these products. This requirement ensures that despite the non-compliance with the sponsor name on the label, the information and presentation of the therapeutic goods remain consistent with the approved standards. The consent is also subject to the conditions set by the delegate, which could include additional requirements to monitor the distribution and use of these products closely, ensuring they are used appropriately and safely within the approved parameters. Failure to comply with the conditions of this consent, or any other terms imposed by the Secretary, may result in legal consequences. Although the specific penalties are not outlined in the notice, breaches of the Therapeutic Goods Act 1989 can lead to significant civil or criminal penalties. For instance, Section 32DA of the Act provides for fines and imprisonment for breaches related to therapeutic goods, with maximum penalties including substantial fines and imprisonment for up to five years for serious offences. Additionally, Section 33 allows for the imposition of pecuniary penalties for breaches of the Act, with the amount of the penalty determined by the court based on the nature and extent of the contravention. The Act also includes provisions for the TGA to take enforcement actions, such as issuing infringement notices or pursuing legal action against entities that fail to comply with the Act's requirements. These actions are aimed at ensuring that therapeutic goods are safe, of high quality, and appropriately labelled, thereby protecting public health and safety. The consent granted under Sections 14 and 14A is thus carefully regulated, with clear obligations and potential consequences for any non-compliance to ensure the therapeutic goods are handled responsibly and ethically.